white → orange2 → red2
Not yet reviewed: this article is pending editorial review by Lyrea.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
2C-iP
2C-iP
hidden
2C-iP is a synthetic psychedelic of the substituted phenethylamine class and a member of the 2C-x family. First synthesized by Dmitri Ger, it is a structural analogue of 2C-P featuring a branched isopropyl side chain. Described as relatively potent and long-acting, it exhibits slightly shorter duration and lower potency compared to 2C-P. It has been sold online as a designer drug with limited documentation of its effects and safety profile.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~5 mg
Light5-15 mg
Moderate15-30 mg
Strong30-45 mg
Heavy30-45 mg
Duration
Onset45-90 minutes
After Effects4-8 hours
Total12-16 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
2C-iP produces a psychedelic experience combining euphoria, empathy, and insight with both mental and physical stimulation. Perception is noticeably altered, with brightened colors and visuals occurring with eyes both open and closed, alongside a softening of the sense of self. As with other members of the 2C series, the experience carries a stimulating character that can shade into restlessness.
Physical
The body load is stimulating, with restlessness, decreased appetite, pupil dilation, muscle tension, alternating sweating and chills, and difficulty sleeping.
Stimulation
Uncomfortable
Cognitive
The headspace is euphoric and empathogenic, with enhanced insight, mental stimulation, and a gentle softening of ego boundaries; confusion can also occur.
Emotional
Visual
Visual effects include brightened colors and imagery visible with both open and closed eyes.
Tactile
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacology not written up yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Cross Tolerance
Serotonergic psychedelics (compounds acting primarily through 5-HT2A receptor agonism)
Harm Potential
Toxicity
Neuromuscular and autonomic
Listed effects include restlessness, sweating or chills, muscle tension, pupil dilation, decreased appetite, and physical stimulation.
Mental status and sleep
Listed effects include confusion and insomnia.
History & Culture
2C-iP, also known by the alternative name "Jelena," is a psychedelic phenethylamine first synthesized by Dmitri Ger. The compound is a structural analogue of 2C-P and has been distributed through online markets as a designer drug. Limited documentation exists regarding the precise timeline of its synthesis or initial appearance in research chemical markets.
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
By Country
Illegal5
CanadaIllegalClassified as a controlled substance under Schedule III of the Controlled Drugs and Substances Act as of October 31, 2016.5 Schedule III substances are subject to criminal penalties for possession, trafficking, and production without authorization, though penalties are generally less severe than those for Schedule I and II substances.
GermanyIllegal (analog/blanket ban)2C-iP is covered as a 2-phenethylamine-derived compound under Anlage 1 Nr. 1: its phenyl ring bears permitted alkoxy and alkyl substituents, and its 2-aminoethyl side chain fits the defined structure. Section 3 prohibits trade, placing on the market, manufacture, import/export/transit, acquisition, possession, and administration of a substance in that group, subject to the statute’s stated exceptions.
NetherlandsIllegal (analog/blanket ban)Opiumwet, lijst IA11
2C-iP is covered by the Opiumwet's List IA structural group for substances derived from 2-phenethylamine. Its 2,5-dimethoxy-4-isopropyl phenyl ring and unsubstituted 2-aminoethyl side chain fall within the listed permitted ring and side-chain substitutions. Article 2a prohibits importing, preparing, processing, selling, supplying, transporting, possessing, and manufacturing a substance in a List IA group, subject to the statutory exceptions.
NorwayIllegalForskrift om narkotika (narkotikaforskriften), FOR-2013-02-14-199 § 5 and vedlegg I; amended by FOR-2024-09-26-230167
2C-iP is expressly listed in vedlegg I to the current Norwegian narcotics regulation, with four chemical-name variants. Section 5 prohibits acquiring, possessing, using, importing, exporting, sending, or transferring narcotics without lawful authority; the 2024 amendment added the 2C-iP listing.
United KingdomIllegal (analog/blanket ban)Misuse of Drugs Act 1971, Schedule 2, Part I, paragraph 1(c)12
2C-iP is covered as a Class A controlled drug under the Act's generic phenethylamine provision. The provision covers compounds structurally derived from phenethylamine by ring substitution with alkyl or alkoxy substituents; 2C-iP is 2,5-dimethoxy-4-isopropylphenethylamine and has both permitted substituent types. The Act also includes its stereoisomers, esters, ethers, salts, and preparations within the Class A schedule where applicable.
References
Source Pages
Citations
- Controlled Drugs and Substances Act, Schedule III, item 35. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/section-sched95602.html1
- Controlled Drugs and Substances Act, Schedule III, item 35. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/c-38.8/section-4.html1
- Controlled Drugs and Substances Act, Schedule III, item 35. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/c-38.8/section-5.html1
- Controlled Drugs and Substances Act, Schedule III, item 35. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/c-38.8/section-7.html1
- Order Amending Schedule III to the Controlled Drugs and Substances Act (2C-phenethylamines). Government of Canada (2016-05-04). https://gazette.gc.ca/rp-pr/p2/2016/2016-05-04/html/sor-dors73-eng.html1
- Forskrift om narkotika (narkotikaforskriften), FOR-2013-02-14-199 § 5 and vedlegg I; amended by FOR-2024-09-26-2301. lovdata.no (n.d.). https://lovdata.no/dokument/SF/forskrift/2013-02-14-1991
- Forskrift om narkotika (narkotikaforskriften), FOR-2013-02-14-199 § 5 and vedlegg I; amended by FOR-2024-09-26-2301. lovdata.no (n.d.). https://lovdata.no/dokument/LTI/forskrift/2024-09-26-23011
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1; § 2 Nr. 1 Buchstabe a; § 3 Abs. 1 Nr. 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1; § 2 Nr. 1 Buchstabe a; § 3 Abs. 1 Nr. 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__2.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1; § 2 Nr. 1 Buchstabe a; § 3 Abs. 1 Nr. 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 2C-iP article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
